Skip to main content

human-bovine reassortant rotavirus strain G1 vaccine

Generic: human-bovine reassortant rotavirus strain G1 vaccine·Brand: RotaTeq

human-bovine reassortant rotavirus strain G1 vaccine: 3 clinical trials tracked.

human-bovine reassortant rotavirus strain G1 vaccine evidence translation

What we can confirm

3 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about human-bovine reassortant rotavirus strain G1 vaccine, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence0 indications · 1 study sponsors

Related indications

No linked indication is available.

Clinical Trial Registry Records (3)

A Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group, 4-arm Study to Investigate the Mixed Vaccination Schedules of a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers

NCT06824181Registry updated 2026-02-13·Phase 3·SNY
Active, not recruiting

Primary endpoint: Presence of any immediate adverse events (AEs)

InterventionalRandomizedquadruple580 targetStarted 2025-02Completion 2027-0927 sites · Chile, Mexico, Philippines, United StatesSanofi

A Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group, 2 Arm Study to Investigate the Safety of a 4-dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers

NCT06824194Registry updated 2026-04-13·Phase 3·SNY
Active, not recruiting

Primary endpoint: Presence of any immediate adverse events (AEs)

InterventionalRandomizedquadruple2,360 targetStarted 2025-02Completion 2027-1050 sites · United StatesSanofi

A Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group, 2-arm Study to Investigate the Safety and Immunogenicity of a 4-dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers

NCT06736041Registry updated 2026-04-22·Phase 3
Active, not recruiting

Primary endpoint: Seroresponse rate for PCV21 serotypes

InterventionalRandomizedquadruple1,714 targetStarted 2024-12Completion 2027-0550 sites · United StatesSanofi Pasteur, a Sanofi Company